171 related articles for article (PubMed ID: 23372746)
21. Synergistic effects of foretinib with HER-targeted agents in MET and HER1- or HER2-coactivated tumor cells.
Liu L; Shi H; Liu Y; Anderson A; Peterson J; Greger J; Martin AM; Gilmer TM
Mol Cancer Ther; 2011 Mar; 10(3):518-30. PubMed ID: 21252284
[TBL] [Abstract][Full Text] [Related]
22. Trastuzumab Specific Epitope Evaluation as a Predictive and Prognostic Biomarker in Gastric Cancer Patients.
Koh J; Nam SK; Lee YW; Kim JW; Lee KW; Ock CY; Oh DY; Ahn SH; Kim HH; Kang KW; Kim WH; Lee HY; Lee HS
Biomolecules; 2019 Nov; 9(12):. PubMed ID: 31779184
[TBL] [Abstract][Full Text] [Related]
23. Large-scale analysis of KMT2 mutations defines a distinctive molecular subset with treatment implication in gastric cancer.
Wang J; Xiu J; Baca Y; Battaglin F; Arai H; Kawanishi N; Soni S; Zhang W; Millstein J; Salhia B; Goldberg RM; Philip PA; Seeber A; Hwang JJ; Shields AF; Marshall JL; Astsaturov I; Craig Lockhart A; Gatalica Z; Michael Korn W; Lenz HJ
Oncogene; 2021 Jul; 40(30):4894-4905. PubMed ID: 34163031
[TBL] [Abstract][Full Text] [Related]
24. Poor efficacy response to trastuzumab therapy in advanced gastric cancer with homogeneous HER2 positive and non-intestinal type.
Xu C; Liu Y; Jiang D; Li Q; Ge X; Zhang Y; Huang J; Su J; Ji Y; Hou J; Lu S; Hou Y; Liu T
Oncotarget; 2017 May; 8(20):33185-33196. PubMed ID: 28388541
[TBL] [Abstract][Full Text] [Related]
25. JWA loss promotes cell migration and cytoskeletal rearrangement by affecting HER2 expression and identifies a high-risk subgroup of HER2-positive gastric carcinoma patients.
Qian J; Zhu W; Wang K; Ma L; Xu J; Xu T; Røe OD; Li A; Zhou J; Shu Y
Oncotarget; 2016 Jun; 7(24):36865-36884. PubMed ID: 27167206
[TBL] [Abstract][Full Text] [Related]
26. cMET and phospho-cMET protein levels in breast cancers and survival outcomes.
Raghav KP; Wang W; Liu S; Chavez-MacGregor M; Meng X; Hortobagyi GN; Mills GB; Meric-Bernstam F; Blumenschein GR; Gonzalez-Angulo AM
Clin Cancer Res; 2012 Apr; 18(8):2269-77. PubMed ID: 22374333
[TBL] [Abstract][Full Text] [Related]
27. Expression Profile of Markers for Targeted Therapy in Gastric Cancer Patients: HER-2, Microsatellite Instability and PD-L1.
Pereira MA; Ramos MFKP; Dias AR; Faraj SF; Ribeiro RRE; de Castria TB; Zilberstein B; Alves VAF; Ribeiro U; de Mello ES
Mol Diagn Ther; 2019 Dec; 23(6):761-771. PubMed ID: 31595457
[TBL] [Abstract][Full Text] [Related]
28. Phosphorylation of cMet tyrosine residues in murine ascitic hepatic cancer cell lines with different lymph node metastatic potentials.
Li Y; Huang X; Zhang Q; Ma K
Mol Med Rep; 2013 Aug; 8(2):655-61. PubMed ID: 23778885
[TBL] [Abstract][Full Text] [Related]
29. Volitinib, a potent and highly selective c-Met inhibitor, effectively blocks c-Met signaling and growth in c-MET amplified gastric cancer patient-derived tumor xenograft models.
Gavine PR; Ren Y; Han L; Lv J; Fan S; Zhang W; Xu W; Liu YJ; Zhang T; Fu H; Yu Y; Wang H; Xu S; Zhou F; Su X; Yin X; Xie L; Wang L; Qing W; Jiao L; Su W; Wang QM
Mol Oncol; 2015 Jan; 9(1):323-33. PubMed ID: 25248999
[TBL] [Abstract][Full Text] [Related]
30. STAT3 signaling drives EZH2 transcriptional activation and mediates poor prognosis in gastric cancer.
Pan YM; Wang CG; Zhu M; Xing R; Cui JT; Li WM; Yu DD; Wang SB; Zhu W; Ye YJ; Wu Y; Wang S; Lu YY
Mol Cancer; 2016 Dec; 15(1):79. PubMed ID: 27938379
[TBL] [Abstract][Full Text] [Related]
31. A large cohort of consecutive patients confirmed frequent HER2 positivity in gastric carcinomas with advanced stages.
Cho J; Jeong J; Sung J; Sung CO; Kim KM; Park CK; Choi MG; Sohn TS; Bae JM; Kim S
Ann Surg Oncol; 2013 Dec; 20 Suppl 3():S477-84. PubMed ID: 23274580
[TBL] [Abstract][Full Text] [Related]
32. Protein expression of HER2, 3, 4 in gastric cancer: correlation with clinical features and survival.
He XX; Ding L; Lin Y; Shu M; Wen JM; Xue L
J Clin Pathol; 2015 May; 68(5):374-80. PubMed ID: 25731189
[TBL] [Abstract][Full Text] [Related]
33. Programmed death-ligand 1 expression in gastric cancer: correlation with mismatch repair deficiency and HER2-negative status.
Wang L; Zhang Q; Ni S; Tan C; Cai X; Huang D; Sheng W
Cancer Med; 2018 Jun; 7(6):2612-2620. PubMed ID: 29673110
[TBL] [Abstract][Full Text] [Related]
34. Testican-1-mediated epithelial-mesenchymal transition signaling confers acquired resistance to lapatinib in HER2-positive gastric cancer.
Kim HP; Han SW; Song SH; Jeong EG; Lee MY; Hwang D; Im SA; Bang YJ; Kim TY
Oncogene; 2014 Jun; 33(25):3334-41. PubMed ID: 23873022
[TBL] [Abstract][Full Text] [Related]
35. Evolutionary Expression of HER2 Conferred by Chromosome Aneuploidy on Circulating Gastric Cancer Cells Contributes to Developing Targeted and Chemotherapeutic Resistance.
Li Y; Zhang X; Liu D; Gong J; Wang DD; Li S; Peng Z; Li Y; Wang X; Lin PP; Li M; Shen L
Clin Cancer Res; 2018 Nov; 24(21):5261-5271. PubMed ID: 30012565
[No Abstract] [Full Text] [Related]
36. Low-scale phosphoproteome analyses identify the mTOR effector p70 S6 kinase 1 as a specific biomarker of the dual-HER1/HER2 tyrosine kinase inhibitor lapatinib (Tykerb) in human breast carcinoma cells.
Vazquez-Martin A; Oliveras-Ferraros C; Colomer R; Brunet J; Menendez JA
Ann Oncol; 2008 Jun; 19(6):1097-109. PubMed ID: 18283037
[TBL] [Abstract][Full Text] [Related]
37. RON (MST1R) is a novel prognostic marker and therapeutic target for gastroesophageal adenocarcinoma.
Catenacci DV; Cervantes G; Yala S; Nelson EA; El-Hashani E; Kanteti R; El Dinali M; Hasina R; Brägelmann J; Seiwert T; Sanicola M; Henderson L; Grushko TA; Olopade O; Karrison T; Bang YJ; Kim WH; Tretiakova M; Vokes E; Frank DA; Kindler HL; Huet H; Salgia R
Cancer Biol Ther; 2011 Jul; 12(1):9-46. PubMed ID: 21543897
[TBL] [Abstract][Full Text] [Related]
38. Phosphorylated insulin-like growth factor-1 receptor expression predicts poor prognosis of Chinese patients with gastric cancer.
Deng WY; Li N; Wan XB; Luo SX; Zhang YW
Med Oncol; 2014 Dec; 31(12):141. PubMed ID: 25348345
[TBL] [Abstract][Full Text] [Related]
39. Met-HER3 crosstalk supports proliferation via MPZL3 in MET-amplified cancer cells.
Stern YE; Al-Ghabkari A; Monast A; Fiset B; Aboualizadeh F; Yao Z; Stagljar I; Walsh LA; Duhamel S; Park M
Cell Mol Life Sci; 2022 Mar; 79(3):178. PubMed ID: 35249128
[TBL] [Abstract][Full Text] [Related]
40. Activation of HER family members in gastric carcinoma cells mediates resistance to MET inhibition.
Corso S; Ghiso E; Cepero V; Sierra JR; Migliore C; Bertotti A; Trusolino L; Comoglio PM; Giordano S
Mol Cancer; 2010 May; 9():121. PubMed ID: 20500904
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]